Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Birk, Navina K, Jain, Saniya, Massoud, Louis, Ramesh, Diya, Monday, Lea, Muma, Bruce, Williams, Jonathan, Alangaden, George, Ramesh, Mayur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214182/
https://www.ncbi.nlm.nih.gov/pubmed/35859992
http://dx.doi.org/10.1093/ofid/ofac282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214182/
https://www.ncbi.nlm.nih.gov/pubmed/35859992
http://dx.doi.org/10.1093/ofid/ofac282

Ejemplares similares